Weird Xience: Abbott Will Launch The Guidant Stent Before Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific plans to launch the Xience drug-eluting stent three months after the same stent is introduced by licensing partner Abbott, giving Abbott a short-term sales advantage
You may also be interested in...
Boston Scientific, Guidant Close The Deal Following FTC Approval
Boston Scientific closed its $28 bil. acquisition of Guidant on April 21, one day after the Federal Trade Commission approved the deal - the largest medical device acquisition in history
Boston Scientific, Guidant Close The Deal Following FTC Approval
Boston Scientific closed its $28 bil. acquisition of Guidant on April 21, one day after the Federal Trade Commission approved the deal - the largest medical device acquisition in history
Abbott loses pharma head
Jeffrey Leiden, PhD, steps down as president of the firm's pharmaceutical products group, to be replaced by medical products group head Richard Gonzalez, effective March 27. The move makes Gonzalez president and COO for all operations of the corporation, Abbott says. The change comes as the company begins to focus more on the medical device side of its business with its impending $7 bil. acquisition of Guidant's vascular and endovascular businesses - the spoils of Boston Scientific's acquisition of Guidant (1"The Gray Sheet" March 20, 2006, p. 18)...